Impact of a pharmacist on drug costs in a coronary care unit

American Journal of Health-System Pharmacy

Volumn 58, Issue 6, 2001, Pages 497-503

  Gandhi, P J ^a   Smith, B S ^a   Tataronis, G R ^a   Maas, B ^a  

^a MA Coll of Pharm and Hlth Sci   (United States)

Author keywords

Cardiac drugs; Clinical pharmacists; Clinical pharmacy; Costs; Interventions; Pharmaceutical services; Pharmacy institutional, hospital

Indexed keywords

ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; NARCOTIC AGENT; PROTON PUMP INHIBITOR; SUCRALFATE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; COST CONTROL; FEMALE; HOSPITAL PHARMACY; HUMAN; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PRIORITY JOURNAL;

EID: 0035868799     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.6.497     Document Type: Article

References (17)

1. Projecting future drug expenditures - 1998
2. Projecting future drug expenditures - 1999
3. Projecting future drug expenditures - 2000
4. Economic evaluations of clinical pharmacy services - 1988-1995
5. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions
6. Pharmaceutical care in medical progressive care patients
7. Impact of a clinical pharmacist in a multidisciplinary intensive care unit
8. Impact of clinical pharmacy services on prescribing on a cardiothoracic/vascular surgical unit
9. Evaluation of the contribution of clinical pharmacists: Inpatient care and cost reduction
10. Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit
11. Effect of pharmacist interventions on drug therapy costs in a surgical intensive-care unit
12. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit
13. Staffing and the cost of clinical and hospital pharmacy services in United States hospitals
14. Abciximab facilitates the rate and extent of thrombolysisi: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
15. Combined thrombolytic and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction
16. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction